Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Puran T4 vs Eutirox NF in Healthy Subjects
NCT04037748Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Jun 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of levothyroxine sodium in hypothyroidism (2 arms), sponsored by Merck KGaA. Primary endpoints: Baseline Corrected Maximum Observed Plasma Concentration at 72 hours and Baseline Corrected Area Under The Plasma Concentration-time Curve From Time Zero to 72 Hours. Started Jun 2019; status: completed.
02
Drugs
levothyroxine sodium
03
Conditions
hypothyroidism
Beyond the preview
Go deeper on NCT04037748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04037748.